Patient-derived xenografts recapitulate molecular features of human uveal melanomas

Molecular Oncology

Volumn 7, Issue 3, 2013, Pages 625-636

  Laurent, Cécile ^a,b,c   Gentien, David ^a   Piperno Neumann, Sophie ^a   Némati, Fariba ^a   Nicolas, André ^a   Tesson, Bruno ^a,b,c   Desjardins, Laurence ^a   Mariani, Pascale ^a   Rapinat, Audrey ^a   Sastre Garau, Xavier ^a   Couturier, Jérôme ^a   Hupé, Philippe ^a,b,c,d   de Koning, Leanne ^a   Dubois, Thierry ^a   Roman Roman, Sergio ^a   Stern, Marc Henri ^e   Barillot, Emmanuel ^a,b,c   Harbour, J William ^f   Saule, Simon ^g   Decaudin, Didier ^a  

^a INSTITUT CURIE   (France)

^b INSERM U900   (France)

^c PSL RESEARCH UNIVERSITY   (France)

^d INSTITUT CURIE   (France)

^e INSTITUT CURIE   (France)

^f USA   (United States)

^g Centre National de la Recherche Scientifique   (France)

Author keywords

Gene expression profiling; Genome profiling; GNAQ GNA11 BAP1 mutations; RPPA; Uveal melanoma; Xenografts

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; COPY NUMBER VARIATION; EXON; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC CONSERVATION; GENETIC STABILITY; HUMAN; IN VIVO STUDY; MOLECULAR BIOLOGY; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SIGNAL TRANSDUCTION; UVEA MELANOMA; XENOGRAFT;

MUS;

EID: 84878111204     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.02.004     Document Type: Article

References (44)

1. Armengol G., et al. DNA copy number changes and evaluation of MYC, IGF1R, and FES amplification in xenografts of pancreatic adenocarcinoma. Cancer Genet. Cytogenet. 2000, 116(2):133-141.
2. Augsburger J.J., Corrêa Z.M., Shaikh A.H. Effectiveness of treatments for metastatic uveal melanoma. Am. J. Ophthalmol. 2009, 148(1):119-127.
3. Bauer J., et al. Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Br. J. Cancer 2009, 101(5):813-815.
4. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Roy. Statist. Soc. Ser. 1995, B 57(1):289-300.
5. Bergamaschi A., et al. Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol. Oncol. 2009, 3(5-6):469-482.
6. Borgmann A., et al. Childhood all blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice. Pediatr. Hematol. Oncol. 2000, 17(8):635-650.
7. Caux-Moncoutier V., et al. EMMA, a cost- and time-effective diagnostic method for simultaneous detection of point mutations and large-scale genomic rearrangements: application to BRCA1 and BRCA2 in 1,525 patients. Hum. Mutat. 2011, 32(3):325-334.
8. Claes A., et al. Phenotypic and genotypic characterization of orthotopic human glioma models and its relevance for the study of anti-glioma therapy. Brain Pathol. 2008, 18(3):423-433.
9. Dai M., et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 2005, 33(20):e175.
10. Damato B., Dopierala J.A., Coupland S.E. Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin. Cancer Res. 2010, 16(24):6083-6092.
11. Falcon S., Gentleman R. Using GOstats to test gene lists for GO term association. Bioinformatics 2007, 23(2):257-258.
12. Garber K. From human to mouse and back: 'tumorgraft' models surge in popularity. J. Natl. Cancer Inst. 2009, 101(1):6-8.
13. Gautier L., Cope L., Bolstad B.M., Irizarry R.A. Affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004, 20(3):307-315.
14. Harbour J.W., et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010, 330(6009):1410-1413.
15. Häusler T., et al. Loss of heterozygosity of 1p in uveal melanomas with monosomy 3. Int. J. Cancer 2005, 116(6):909-913.
16. Houdayer C., et al. Enhanced mismatch mutation analysis: simultaneous detection of point mutations and large scale rearrangements by capillary electrophoresis, application to BRCA1 and BRCA2. Methods Mol. Biol. 2010, 653:147-180.
17. Hu J., et al. Non-parametric quantification of protein lysate arrays. Bioinformatics 2007, 23(15):1986-1994.
18. Hupé P., et al. Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics 2004, 20(18):3413-3422.
19. Indraccolo S., et al. Establishment and characterization of xenografts and cancer cell cultures derived from BRCA1 -/- epithelial ovarian cancers. Eur. J. Cancer 2006, 42(10):1475-1483.
20. Jeuken J.W., et al. Genetic reflection of glioblastoma biopsy material in xenografts: characterization of 11 glioblastoma xenograft lines by comparative genomic hybridization. J. Neurosurg. 2000, 92(4):652-658.
21. Marangoni E., et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin. Cancer Res. 2007, 13(13):3989-3998.
22. Mariani P., et al. Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie. Eur. J. Surg. Oncol. 2009, 35(11):1192-1197.
23. Mosteller F., Tukey J. Data Analysis and Regression: a Second Course in Statistics 1977, s.l.: Addison-Wesley Pub. Co.
24. Némati F., et al. Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. Clin. Cancer Res. 2010, 16(8):2352-2362.
25. Onken M.D., et al. Collaborative ocular oncology group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 2012, 119(8):1596-1603.
26. Onken M.D., et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2008, 49(12):5230-5234.
27. Onken M.D., et al. Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. Clin. Cancer Res. 2007, 13(10):2923-2927.
28. Onken M.D., Worley L.A., Tuscan M.D., Harbour J.W. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J. Mol. Diagn. 2010, 12(4):461-468.
29. Patel M., et al. Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin. Cancer Res. 2011, 17(8):2087-2100.
30. Plater L.D., et al. Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. Br. J. Cancer 2010, 103(8):1192-1200.
31. Prescher G., Bornfeld N., Horsthemke B., Becher R. Chromosomal aberrations defining uveal melanoma of poor prognosis. Lancet 1992, 339(8794):691-692.
32. Press J.Z., et al. Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecol. Oncol. 2008, 110(2):256-264.
33. Reyal F., et al. Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res. 2012, 14(1):R11.
34. Rigaill G. Pruned Dynamic Programming for Optimal Multiple Change-point Detection 2010, ArXiv, (e-prints).
35. Rubio-Viqueira B., et al. An in vivo platform for translational drug development in pancreatic cancer. Clin. Cancer Res. 2006, 12(15):4652-4661.
36. Servant N., et al. EMA - a R package for easy microarray data analysis. BMC Res. Notes 2010, 3:277.
37. Smyth G.K. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 2004, 3. p. Article 3.
38. Smyth G.K. Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions Using R and Bioconductor 2005, 397-420. s.l.: Springer. R. Dans, V. Gentleman, S. Carey, W.H.R. Dudoit (Eds.).
39. Subramaniam M.M., et al. Tissue microarray profiling of primary and xenotransplanted synovial sarcomas demonstrates the immunophenotypic similarities existing between SYT-SSX fusion gene confirmed, biphasic, and monophasic fibrous variants. Virchows Arch. 2006, 449(4):435-447.
40. Trolet J., et al. Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases. Invest. Ophthalmol. Vis. Sci. 2009, 50(6):2572-2580.
41. Van C.D., et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009, 457(7229):599-602.
42. Van C.D., et al. Mutations in GNA11 in uveal melanoma. N. Engl. J. Med. 2010, 363(23):2191-2199.
43. Weber J., et al. High-throughput simultaneous detection of point mutations and large-scale rearrangements by CE. Electrophoresis 2007, 28(23):4282-4288.
44. White J.S., et al. Correlation of comparative genomic hybridization results of 100 archival uveal melanomas with patient survival. Cancer Genet. Cytogenet. 2006, 170(1):29-39.